AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Platelet-activating factor acetylhydrolase 2, cytoplasmic

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q99487

UPID:

PAFA2_HUMAN

Alternative names:

PAF:lysophospholipid transacetylase; PAF:sphingosine transacetylase; Platelet-activating factor acetyltransferase PAFAH2; Serine-dependent phospholipase A2

Alternative UPACC:

Q99487; D3DPK1; O15458; Q5SY02

Background:

Platelet-activating factor acetylhydrolase 2, cytoplasmic (PAFAH2) plays a pivotal role in lipid metabolism by hydrolyzing the acetyl group at the sn-2 position of platelet-activating factor (PAF) and its analogs. This enzymatic action leads to the inactivation of PAF, a potent phospholipid activator involved in various biological processes. PAFAH2 exhibits specificity for phospholipids with short acyl chains and is capable of catalyzing transacetylation reactions, producing plasmalogen analogs of PAF and N-acetylsphingosine.

Therapeutic significance:

Understanding the role of Platelet-activating factor acetylhydrolase 2, cytoplasmic could open doors to potential therapeutic strategies. Its involvement in lipid metabolism and the regulation of bioactive lipids highlights its potential as a target for modulating inflammatory responses and other PAF-related pathologies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.